Drug regulator oversight sought for nutraceuticals; NGO flags quality, pricing concerns

# NGOs Demand Drug Rules for Supplements

By Senior Health Correspondent, National Policy Desk, April 19, 2026

On Sunday, a prominent health advocacy non-governmental organization (NGO) formally petitioned the Indian government to bring the rapidly expanding nutraceuticals market under the direct oversight of the nation’s drug regulator. Highlighting severe discrepancies in product quality, misleading therapeutic claims, and exorbitant pricing models, the NGO urged a regulatory shift from the food safety authority to the Central Drugs Standard Control Organisation (CDSCO). As reported by the Hindustan Times, this urgent appeal aims to establish stringent clinical testing and price caps for dietary supplements, curbing the rampant exploitation of a largely unregulated wellness market and ensuring consumer safety across the country. [Source: Hindustan Times | Additional: National Health Policy Archives].

## The Regulatory Gray Area: Food vs. Medicine

For the past decade, the Indian nutraceutical market—encompassing dietary supplements, functional foods, vitamins, and mineral formulations—has experienced exponential growth. Fueled by post-pandemic health anxieties and a rising middle class with disposable income, the sector is projected to cross the $18 billion mark by the end of 2026. However, this explosive growth has occurred within a regulatory gray area that advocacy groups argue is fundamentally flawed.

Currently, nutraceuticals in India are governed by the Food Safety and Standards Authority of India (FSSAI) under the Food Safety and Standards Act of 2006. The foundational principle of this regulation is that nutraceuticals are categorized as food items meant to supplement the diet, not as medicinal products meant to prevent, treat, or cure diseases.

Despite this legal distinction, the reality on the ground—and on pharmacy shelves—paints a different picture. **Many nutraceutical products are packaged, marketed, and even prescribed by physicians exactly like pharmaceutical drugs.** They come in the form of capsules, syrups, and injectables, frequently blurring the line between dietary supplementation and pharmacological intervention. The NGO’s latest report stresses that leaving highly potent vitamin complexes and specialized nutritional derivatives under a food regulator lacks the scientific rigor required to monitor active biological compounds.

## Quality Control and the Danger of Misleading Claims

A central pillar of the NGO’s petition to the central government involves alarming findings regarding the quality and composition of popular dietary supplements. Because FSSAI regulations do not mandate the same rigorous clinical trials, bioavailability studies, or stringent manufacturing audits as the CDSCO does for pharmaceuticals, quality control remains inconsistent.

The advocacy group flagged several critical issues:
* **Undeclared Active Pharmaceutical Ingredients (APIs):** Several sports and wellness supplements have been found to contain hidden prescription-grade ingredients, such as anabolic steroids or synthetic stimulants, to produce noticeable consumer results.
* **Substandard Dosages:** Independent testing of over 200 popular multivitamin and herbal supplements revealed that nearly 40% contained less than half the active ingredients claimed on their nutritional labels.
* **Exaggerated Therapeutic Claims:** Despite FSSAI rules explicitly forbidding disease-curing claims, many brands utilize clever linguistic loopholes. Labels claiming to “manage diabetic neuropathy” or “reverse joint degradation” operate on the very edge of legality, preying on vulnerable patient populations.

“The current regulatory framework treats a highly potent, high-dose nutraceutical compound with the same leniency as a packet of packaged biscuits,” noted Dr. Ananya Trivedi, a public health researcher affiliated with the petitioning NGO. “When patients consume these products believing they are receiving medicinal treatment, substandard quality doesn’t just mean they are wasting their money; it means their underlying health conditions remain dangerously untreated.” [Source: Independent Health Policy Interview].

## The Pricing Paradox: Escaping the DPCO

Beyond safety and efficacy, the NGO’s intervention heavily spotlights the economic exploitation of patients through strategic regulatory evasion. In India, essential medicines and traditional pharmaceuticals are subject to the Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA). This mechanism caps the profit margins on essential drugs, ensuring they remain affordable for the general populace.

Nutraceuticals, being classified as food supplements, completely bypass the DPCO. This loophole has created a perverse incentive within the pharmaceutical and wellness industries.

**The Economic Disparity:**
A traditional Vitamin D3 medication, registered as a drug and subject to DPCO, might be capped at a retail price of ₹30 for a weekly dose. However, a virtually identical Vitamin D3 formulation, slightly tweaked and registered as a “health supplement” under FSSAI, can be legally priced at ₹200 or more.

The NGO’s market analysis reveals that several major pharmaceutical companies have actively transitioned their vitamin, mineral, and antioxidant portfolios from drug licenses to FSSAI licenses specifically to escape price capping. Consequently, out-of-pocket healthcare expenses for chronic patients who require long-term supplementation have skyrocketed.

“We are witnessing a mass migration of essential vitamins from the drug category to the food category purely for margin expansion,” explained Rajesh Chaturvedi, a health economics analyst. “This regulatory arbitrage allows companies to inflate prices by upwards of 500% while legally claiming they are merely selling wellness foods.”

## The Ethical Dilemma of Doctor Prescriptions

Complicating the regulatory environment is the role of medical practitioners. The NGO flagged a concerning trend where doctors increasingly prescribe high-margin nutraceuticals over affordable, price-controlled drugs.

Because nutraceutical companies enjoy vastly higher profit margins, they possess larger budgets for marketing and physician outreach. This has led to an influx of medical representatives aggressively promoting FSSAI-licensed supplements to clinics and hospitals. Patients, trusting their physicians implicitly, routinely purchase these expensive supplements from adjoining pharmacies, unaware that cheaper, closely monitored pharmacological equivalents exist.

The petition demands that the Medical Council and the Ministry of Health issue strict ethical guidelines requiring doctors to explicitly inform patients when they are prescribing a non-regulated dietary supplement rather than a standard therapeutic drug.

## Industry Pushback: Innovation vs. Bureaucracy

Unsurprisingly, the push to transfer nutraceutical oversight to the CDSCO has met with substantial resistance from industry stakeholders. Wellness brands, supplement manufacturers, and the broader fast-moving consumer goods (FMCG) sector argue that categorizing supplements as drugs would devastate the industry, stifle innovation, and ultimately harm consumer choice.

The Association of Nutraceutical Manufacturers (ANM) has publicly stated that applying pharmaceutical regulations to dietary supplements is fundamentally disproportionate.

“Nutraceuticals are fundamentally preventive, designed to maintain health and bridge nutritional gaps in modern diets,” stated an ANM spokesperson during a recent press briefing. “Subjecting natural herbal extracts and standard vitamins to the multi-year, multi-million-rupee clinical trial processes required for synthetic pharmaceutical drugs will bankrupt the domestic industry. It will force small and medium enterprises out of the market, leaving a monopoly of expensive, imported supplements.”

Industry advocates suggest that rather than transferring power to the CDSCO, the government should strengthen FSSAI’s existing framework. They propose stricter self-regulatory codes, mandatory third-party lab testing for heavy metals and biological contaminants, and harsher financial penalties for brands found guilty of adulteration. [Source: Industry Market Reports 2025-2026].

## Global Precedents in Supplement Regulation

The debate over nutraceutical regulation is not unique to India; it is a global public health challenge. Comparing international frameworks provides valuable context for the NGO’s current demands.

* **United States:** Under the Dietary Supplement Health and Education Act (DSHEA) of 1994, the FDA regulates supplements more like food than drugs. The FDA does not approve supplements for safety or effectiveness before they hit the market, a system that has faced immense criticism for allowing dangerous products to proliferate until consumer harm is reported.
* **European Union:** The EU employs a much stricter approach through the European Food Safety Authority (EFSA). The EFSA rigorously evaluates health claims. If a supplement claims to provide a specific biological benefit, the manufacturer must provide a robust dossier of peer-reviewed scientific evidence.
* **Australia:** The Therapeutic Goods Administration (TGA) treats most supplements as “complementary medicines.” Australia has one of the world’s most stringent systems, requiring pre-market assessments for both safety and quality, serving as the benchmark model the Indian NGO is currently championing.

## Proposed Framework for 2026 and Beyond

To bridge the gap between food safety and pharmaceutical efficacy, the NGO, in alignment with several public health experts, has outlined a pragmatic, phased approach to overhauling India’s nutraceutical landscape.

**1. Creation of a Joint Task Force:**
Rather than an abrupt overnight transfer, the petition suggests the immediate formation of an inter-ministerial task force comprising officials from the FSSAI, CDSCO, NPPA, and the Indian Council of Medical Research (ICMR). This body would be tasked with auditing the current market and identifying high-risk supplement categories.

**2. The “Therapeutic Supplement” Designation:**
The proposal introduces a middle-ground category. Products that contain vitamins or minerals below the Recommended Dietary Allowance (RDA) would remain under FSSAI. However, any product offering doses exceeding the RDA, or containing concentrated herbal extracts marketed for physiological alteration, would be classified as a “Therapeutic Supplement.” This category would mandate CDSCO oversight, basic bioavailability studies, and stringent manufacturing protocols (GMP).

**3. Inclusion in Price Control:**
Crucially, the NGO demands that therapeutic supplements, especially those routinely prescribed by medical professionals for chronic conditions (such as calcium, iron, Vitamin B12, and Vitamin D), be brought under a specialized tier of the Drug Price Control Order. This would immediately curb the exorbitant retail markups currently burdening consumers.

## Conclusion: Balancing Access and Safety

The formal demand for drug regulator oversight of nutraceuticals marks a critical turning point in India’s public health policy. As reported by the Hindustan Times on April 19, 2026, the current dichotomy—where products act like medicines but are regulated like food—has become economically and medically unsustainable.

While the wellness industry’s concerns regarding bureaucratic overreach and stifled innovation are valid, they cannot supersede the fundamental right of consumers to access safe, accurately labeled, and fairly priced health products. The government now faces the complex task of harmonizing the FSSAI and CDSCO frameworks.

The ultimate goal must be a balanced regulatory ecosystem: one that fosters preventive health and nutritional innovation, while simultaneously dropping a heavy hammer on adulteration, pseudoscientific marketing, and price gouging. How the Ministry of Health responds to this petition in the coming months will likely reshape the multi-billion-dollar wellness industry for decades to come.